697305-48-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Fluorophenyl)piperazin-2-one hydrochloride is used as a key intermediate for the preparation of selective somatostatin receptor 2 agonists. These agonists are crucial in the treatment of type 2 diabetes, as they help regulate blood glucose levels and improve the overall management of the disease.

Upstream product

• 329079-68-7 N-(4-fluorophenyl)-2-[(2-hydroxyethyl)amino]acetamide 
• 1284243-44-2 tert-butyl 4-(4-fluorophenyl)-3-oxopiperazine-1-carboxylate 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 371-40-4 4-fluoroaniline 
• 351-04-2 2-chloro-N-(4-fluorophenyl)acetamide 

Downstream Products

• 1284243-45-3 4-{[3-chloro-6-(1H-pyrazol-4-yl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-1-(4-fluorophenyl)-2-piperazinone 
• 1284243-40-8 4-{[3-chloro-6-(3-furanyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-1-(4-fluorophenyl)-2-piperazinone 
• 697304-76-0 ethyl (2R,3S)-2-({[4-(4-fluorophenyl)-3-oxopiperazin-1-yl]carbonyl}amino)-3-(1H-indol-3-yl)butanoate 
• 697308-64-8 N-[(1R,2S)-1-({[5-[(dimethylamino)methyl]-2-ethoxyphenyl]amino}carbonyl)-2-(1H-indol-3-yl)propyl]-4-(4-fluorophenyl)-3-oxopiperazine-1-carboxamide 

Relevant academic research and scientific papers

Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes

The discovery of a novel series of β-methyltryptophan (β MeTrp) derivatives as selective and orally active non-peptide somatostatin receptor 2 (SSTR2) agonists for the treatment of Type 2 diabetes is described. In our previous research, Compound A, β-MeTr

Tetrahydroquinazolinone Derivatives as PARP Inhibitors

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

PIPERAZINYL ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.